مکتبة رقمیه للعلوم الطبيه
Your cart is empty.
  • Cart
  • Lists
    Your lists Log in to create your own lists
  • Log in to your account
  • Your cookies
  • Search history
  • Advanced search
  • Authority search
  • Tag cloud
  • Library

Log in to your account

  1. Home
  2. Details for: CD80 binding polyproline helical peptide inhibits T cell activation.
Normal view MARC view ISBD view

CD80 binding polyproline helical peptide inhibits T cell activation. [electronic resource]

By:
  • Srinivasan, Mythily
Contributor(s):
  • Lu, Debao
  • Eri, Rajaraman
  • Brand, David D
  • Haque, Azizul
  • Blum, Janice S
Producer: 20050425Description: 10149-55 p. digitalISSN:
  • 0021-9258
Subject(s):
  • Animals
  • Antigens, CD -- chemistry
  • Antigens, Differentiation -- chemistry
  • Arthritis, Experimental
  • B7-1 Antigen -- chemistry
  • B7-2 Antigen
  • Binding, Competitive
  • CD28 Antigens -- chemistry
  • CTLA-4 Antigen
  • Cell Proliferation
  • Circular Dichroism
  • Collagen -- metabolism
  • Dose-Response Relationship, Drug
  • Enzyme-Linked Immunosorbent Assay
  • Humans
  • Ligands
  • Lymph Nodes -- pathology
  • Lymphocyte Activation
  • Membrane Glycoproteins -- chemistry
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred DBA
  • Models, Molecular
  • Peptides -- chemistry
  • Proline -- chemistry
  • Protein Binding
  • Protein Conformation
  • Protein Structure, Secondary
  • Protein Structure, Tertiary
  • Structure-Activity Relationship
  • T-Lymphocytes -- metabolism
  • Time Factors
Online resources:
  • Available from publisher's website
In: The Journal of biological chemistry vol. 280
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Cancel rating. Average rating: 0.0 (0 votes)
  • Holdings ( 0 )
  • Title notes ( 1 )
  • Comments ( 0 )
No physical items for this record

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

There are no comments on this title.

Log in to your account to post a comment.
Browse results Close
Previous
Back to results
Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 1 [From clinical medicine to experimentation: cerebral vascular accidents, a new field for the use of a coronarodilator, carbochromene].
    by Giovannoni, L
  • 2 Highly fluorescent protein labeling using dendritic peptide derivatives.
    by Giovannoni, L
  • 3 Isolation of anti-angiogenesis antibodies from a large combinatorial repertoire by colony filter screening.
    by Giovannoni, L
  • 4 Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis.
    by Viti, F
  • 5 The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity.
    by Hemmerle, T
  • 6 Open visiting policies in Intensive Care Units may not affect consent to organ donation.
    by Bambi, S
  • 7 Prevalence of genetic risk factors for coronary artery disease in Corsica island (France).
    by Falchi, A
  • 8 A strategy for the isolation of catalytic activities from repertoires of enzymes displayed on phage.
    by Demartis, S
  • 9 Cholesteryl ester transfer protein gene polymorphisms are associated with coronary artery disease in Corsican population (France).
    by Falchi, A
  • 10 Experimental study of argon laser-induced microthrombosis during PGI2 infusion.
    by Boncinelli, S
  • 11 A functional circadian clock is required for proper insulin secretion by human pancreatic islet cells.
    by Saini, C
  • 12 Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours.
    by Spitaleri, G
  • 13 Targeted ED-B fibronectin SPECT in vivo imaging in experimental atherosclerosis.
    by Dietrich, T
  • 14 Autonomous and self-sustained circadian oscillators displayed in human islet cells.
    by Pulimeno, P
  • 15 A phase IB clinical trial with Dekavil (F8-IL10), an immunoregulatory 'armed antibody' for the treatment of rheumatoid arthritis, used in combination wiIh methotrexate.
    by Galeazzi, M
Close

CD80 binding polyproline helical peptide inhibits T cell activation.

APA

Srinivasan M., Lu D., Eri R., Brand D. D., Haque A. & Blum J. S. (20050425). CD80 binding polyproline helical peptide inhibits T cell activation. : The Journal of biological chemistry.

Chicago

Srinivasan Mythily, Lu Debao, Eri Rajaraman, Brand David D, Haque Azizul and Blum Janice S. 20050425. CD80 binding polyproline helical peptide inhibits T cell activation. : The Journal of biological chemistry.

Harvard

Srinivasan M., Lu D., Eri R., Brand D. D., Haque A. and Blum J. S. (20050425). CD80 binding polyproline helical peptide inhibits T cell activation. : The Journal of biological chemistry.

MLA

Srinivasan Mythily, Lu Debao, Eri Rajaraman, Brand David D, Haque Azizul and Blum Janice S. CD80 binding polyproline helical peptide inhibits T cell activation. : The Journal of biological chemistry. 20050425.

  • Print
  • Cite
  • Add to your cart (remove)
  • Save record
    BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
  • More searches
    Search for this title in:
    Other Libraries (WorldCat) Other Databases (Google Scholar) Online Stores (Bookfinder.com) Open Library (openlibrary.org)

Exporting to Dublin Core...

Visit web site